US Markets Recover from Post-Election Slump Amid Positive Clinical Trial Data for Eli Lilly and Johnson & Johnson
Major US indices, including the S&P 500 and Nasdaq, have extended their recovery following a post-election sell-off on Thursday. While Nvidia (NVDA) faced significant pressure due to leadership turmoil, broader market sectors showed strength, particularly in industrials, consumer discretionary, and technology. Key performers included Amazon (AMZN), Micron (MU), and various industrial stocks with data center exposure. The healthcare sector saw notable gains driven by clinical trial updates. Eli Lilly (LLY) rose over 4% following positive results for its weight-loss pill Foundayo in treating obstructive sleep apnea, while Johnson & Johnson (JNJ) climbed over 2% on news regarding its psoriasis pill Icotyde's efficacy in psoriatic arthritis. Despite new FDA warnings regarding rare eye condition risks associated with GLP-1 medications, investor sentiment remained largely positive.
Tickers: $AMZN $COF $ETN $GEV $JNJ $LLY $MU $NVDA $NVO $SBUX
Topics: Clinical Trial Results Pharmaceuticals Stock Market Rally Weight-loss Drugs
Part of the story US Markets Recover from Post-Election Slump Amid Positive Clinical Trial Data for Eli Lilly and Johnson & Johnson (2 articles)